Evommune (EVMN) Equity Average (2024 - 2026)

Evommune (EVMN) has 3 years of Equity Average data on file, last reported at $255.1 million in Q1 2026.

• Equity Average for Q1 2026 came in at $255.1 million, up 268.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $255.1 million (up 268.65% YoY), and the FY2025 annual result was $30.7 million, changed N/A from the prior year.
• Equity Average improved to $255.1 million in Q1 2026 per EVMN's latest filing, from $11.2 million in the prior quarter.
• Over five years, Equity Average peaked at $255.1 million in Q1 2026 and troughed at -$170.7 million in Q3 2025.
• A 3-year average of -$37.8 million and a median of -$133.4 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2025 and 2026: Equity Average soared 108.41% in 2025, then jumped 268.65% in 2026.
• A 3-year view of Equity Average shows it stood at -$133.4 million in 2024, then surged by 108.41% to $11.2 million in 2025, then jumped by 2174.38% to $255.1 million in 2026.
• Business Quant data shows EVMN's Equity Average at $255.1 million in Q1 2026, $11.2 million in Q4 2025, and -$170.7 million in Q3 2025.